Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00511043 · ClinicalTrials.gov registry record · Phase 2
PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma
A Phase 2 study, sponsored by David Rizzieri, MD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00511043: Clinical Trial Phase 2 study, sponsored by David Rizzieri, MD.
NCT00511043 is a Phase 2 study that was terminated before completion, run by David Rizzieri, MD. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00511043, a Phase 2 study, was terminated before completion, sponsored by David Rizzieri, MD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a phase II open label study to assess the efficacy and safety of PTK787/ZK222584 in adults with relapsed or refractory diffuse large cell lymphoma (DLCL). All subjects will receive PTK787/ZK222584. Subjects who tolerate the study target dose of 1250mg will remain on that dose until study completion at 12 months or until disease progression, unacceptable toxicity, withdrawal of consent or non-compliance with the protocol requirement.
Interventions
- DRUG PTK787
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-11 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Why NCT00511043 stopped before completion
NCT00511043 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which PTK787 is the first listed.
NCT00511043 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00511043 about?
NCT00511043 is a clinical study titled "PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma". This is a phase II open label study to assess the efficacy and safety of PTK787/ZK222584 in adults with relapsed or refractory diffuse large cell lymphoma (DLCL). All subjects will receive PTK787/ZK222584. Subjects who tolerate the study target dose of 1250mg will remain on that dose until study com...
What is the current status of trial NCT00511043?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2005-11. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00511043?
The interventions under investigation include: PTK787 (DRUG).
Who is sponsoring clinical trial NCT00511043?
This trial is sponsored by David Rizzieri, MD, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00511043's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia